Compare NOAH & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NOAH | AVIR |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.0M | 413.1M |
| IPO Year | 2010 | 2020 |
| Metric | NOAH | AVIR |
|---|---|---|
| Price | $6.73 | $4.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $10.69 | $8.50 |
| AVG Volume (30 Days) | 154.2K | ★ 279.6K |
| Earning Date | 11-24-2026 | 11-11-2026 |
| Dividend Yield | ★ 10.08% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.74 | $2.87 |
| 52 Week High | $12.45 | $6.45 |
| Indicator | NOAH | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 23.55 | 33.24 |
| Support Level | N/A | $4.06 |
| Resistance Level | $8.17 | $4.46 |
| Average True Range (ATR) | 0.17 | 0.25 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 3.43 | 18.02 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.